Prognostic markers in bladder cancer: A contemporary review of the literature

Journal of Urology

Volumn 160, Issue 3 I, 1998, Pages 645-659

  Stein, John P ^a   Grossfeld, Gary D ^a   Ginsberg, David A ^a   Esrig, David ^a   Freeman, John A ^a   Figueroa, Arsenio J ^a   Skinner, Donald G ^a   Cote, Richard J ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Biological; Bladder neoplasms; Carcinoma; Transitional cell; Tumor markers

Indexed keywords

BLOOD GROUP ANTIGEN; CELL ADHESION MOLECULE; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR; REGULATOR PROTEIN; TUMOR ANTIGEN; TUMOR MARKER;

ANGIOGENESIS; BLADDER CANCER; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CELL CYCLE; CELL INTERACTION; GENE THERAPY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

EID: 0032324353     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)62747-2     Document Type: Review

References (210)

1. Parker, S. L., Tong, T., Bolden, S. and Wingo, P. A.: Cancer statistics, 1997. CA, 47: 5, 1997.
2. Crawford, E. D. and Davis, M. A.: Nontransitional cell carcinomas of the bladder. In: Genitourinary Cancer Management. Edited by J. B. deKernion and D. F. Paulson. Philadelphia: Lea & Febiger, chapt. 4, pp. 95-105, 1987.
3. Skinner, D. G. and Lieskovsky, G.: Management of invasive and high-grade bladder cancer. In: Diagnosis and Management of Genitourinary Cancer. Edited by D. G. Skinner and G. Lieskovsky. Philadelphia: W. B. Saunders, Co., chapt. 16, pp. 295-312, 1988.
4. Droller, M. J.: Individualizing the approach to invasive bladder cancer. Contemp. Urol., July/August, pp. 54-61, 1990.
5. Malkowicz, B. S.: Superficial bladder cancer: the role of molecular markers in the treatment of high-risk superficial disease. Sem. Urol. Oncol., 15: 169, 1997.
6. Taylor, C. R.: The current role of immunohistochemistry in diagnostic pathology. Adv. Path. Lab. Med., 7: 59, 1994.
7. Esrig, D., Spruck, C. H. III, Nichols, P. W., Chaiwun, B., Steven, K., Groshen, S., Chen, S-C., Skinner, D. G., Jones, P. A. and Cote, R. J.: p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Amer. J. Path., 143: 1389, 1993.
8. Vet, J. A., Bringuier, P. P., Schaafsma, H. E., Witjes, J. A., Debruyne, F. M. and Schalken, J. A.: Comparison of p53 protein overexpression with P53 mutation in bladder cancer: clinical and biologic aspects. Lab. Invest., 73: 837, 1995.
9. Cordon-Cardo, C., Dalbagni, D., Saez, G. T., Oliva, M. R., Zhang, Z. F., Rosai, J., Reuter, V. E. and Pellicer, A.: p53 mutations in human bladder cancer: geonotypic versus phenotypic patterns. Int. J. Cancer, 56: 347, 1994.
10. Hakomori, S.: Aberrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives. Cancer Res., 45: 2405, 1985.
11. Köhler, G. and Milstern, C.: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256:495, 1975.
12. Lloyd, K. O.: Philip Levine award lecture. Blood group antigens as markers for normal differentiation and malignant change in human tissues. Amer. J. Clin. Path., 87: 129, 1987.
13. DeCenzo, J. M., Howard, P. and Irish, C. E.: Antigenic deletion and prognosis of patients with stage A transitional cell carcinoma. J. Urol., 114: 874, 1975.
14. Newman, A. J., Jr., Carlton, C. E., Jr. and Johnson, S.: Cell surface A, B, or O(H) blood group antigens as an indicator of malignant potential in stage A bladder carcinoma. J. Urol., 124: 27, 1980.
15. Weinstein, R. S., Alroy, J., Farrow, G. M., Miller, A. W., III and Davidsohn, I.: Blood group isoantigen deletion in carcinoma in situ of the urinary bladder. Cancer, 43: 661, 1979.
16. D'Elia, F. L., Cooper, H. S. and Mulholland, S. G.: ABH isoantigens in stage O papillary transitional cell carcinoma of the bladder: correlation with biological behavior. J. Urol., 127: 665, 1982.
17. Lange, P. H., Limas, C. and Fraley, E. E.: Tissue blood-group antigens and prognosis in low stage transitional cell carcinoma of the bladder. J. Urol., 119: 52, 1978.
18. Young, A. K., Hammond, E. and Middleton, A. W., Jr.: The prognostic value of cell surface antigens in low grade, non-invasive, transitional cell carcinoma of the bladder. J. Urol., 122: 462, 1979.
19. Wiley, E. L., Mendelsohn, G., Droller, M. J. and Eggleston, J. C.: Immunoperoxidase detection of carcinoembryonic antigen and blood group substances in papillary transitional cell carcinoma of the bladder. J. Urol., 128: 276, 1982.
20. Limas, C., Lange, P., Fraley, E. E. and Vessella, R. L.: A, B, H antigens in transitional cell tumors of the urinary bladder: correlation with the clinical course. Cancer, 44: 2099, 1979.
21. Cordon-Cardo, C., Lloyd, K. O., Finstad, C. L., McCroaty, M. E., Reuter, V. E., Bander, N. H., Old, L. J. and Melamed, M. R.: Immunoanatomic distribution of blood group antigens in the human urinary tract. Influence of secretor status. Lab. Invest., 55: 444, 1986.
22. Sarkis, A. S., Charytonowicz, E. and Cordon-Cardo, C.: Blood group antigen expression in bladder tumors: an immunohistochemical study of superficial bladder lesions. J. Exp. Clin. Cancer Res., 13: 139, 1994.
23. Cordon-Cardo, C., Reuter, V. E., Lloyd, K. O., Sheinfeld, J., Fair, W. R., Old, L. J. and Melamed, M. R.: Blood group-related antigens in human urothelium: enhanced expression of precursors, LeX, and LeY determinants in urothelial carcinoma. Cancer Res., 48: 4113, 1988.
24. Sheinfeld, J., Reuter, V. E., Melamed, M. R., Fair, W. R., Morse, M., Sogani, P. C., Herr, H. W., Whitmore, W. F. and Cordon-Cardo, C.: Enhanced bladder cancer detection with the Lewis X antigen as a marker of neoplastic transformation. J. Urol., 143: 285, 1990.
25. Golijanin, D., Sherman, Y., Shapiro, A. and Pode, D.: Detection of bladder tumors by immunostaining of Lewis X antigen in cells from voided urine. Urology, 46: 173, 1995.
26. Sheinfeld, J., Sarkis, A. S., Reuter, V. E., Fair, W. R. and Cordon-Cardo, C.: The Lewis X antigen as a predictor of tumor recurrence in high risk disease-free bladder cancer patients. J. Urol., part 2, 147: 423A, abstract 841, 1992.
27. Dalbagni, G., Reuter, V. E., Sheinfeld, J., Fradet, Y., Fair, W. R. and Cordon-Cardo, C.: Cell surface differentiation antigens of normal urothelium and bladder tumors. Sem. Surg. Oncol., 8: 293, 1992.
28. Fradet, Y. and Cordon-Cardo, C.: Critical appraisal of tumor markers in bladder cancer. Sem. Urol., 11: 145, 1993.
29. Fradet, Y., Gauthier, J., Bédard, G., Charrois, R. and Naud, A.: Monitoring and prognostic determination of bladder tumors by flow cytometry with monoclonal antibodies on bladder irrigations. J. Urol., part 2, 145: 250A, abstract 149, 1991.
30. Fradet, Y., Tardif, M., Bourget, L., Robert, J. and the Laval University Urology Group: Clinical cancer progression in urinary bladder tumors evaluated by multiparameter flow cytometry with monoclonal antibodies. Cancer Res., 50: 432, 1990.
31. Bretton, P., Cordon-Cardo, C., Wartinger, D., Kimmel, M., Fair, W. R., Melamed, M. R. and Fradet, Y.: Expression of the T-138 antigen and survival of patients with bladder cancer. Proc. Amer. Assn. Cancer Res., 31: 186, abstract 1105, 1990.
32. Sarosdy, M. F., de Vere White, R. W., Soloway, M. S., Sheinfeld, J., Hudson, M. A., Schellhammer, P. F., Jarowenko, M. V., Adams, G. and Blumenstein, B. A.: Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J. Urol., 154: 379, 1995.
33. D'Hallewin, M.-A. and Baert, L.: Initial evaluation of the bladder tumor antigen test in superficial bladder cancer. J. Urol., 155: 475, 1996.
34. Johnston, B., Morales, A., Emerson, L. and Lundie, M.: Rapid detection of bladder cancer: a comparative study of point of care tests. J. Urol., 158: 2098, 1997.
35. Murphy, W. M., Rivera-Ramirez, I., Medina, C. A., Wright, N. J. and Wajsman, Z.: The bladder tumor antigen (BTA) test compared to voided urine cytology in the detection of bladder neoplasms. J. Urol., 158: 2102, 1997.
36. Ellis, W. J., Blumenstein, B. A., Ishak, L. M., Enfield, D. L. and the Multi Center Study Group: Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. Urology, 50: 882, 1997.
37. Ishak, L. M., Enfield, D. L. and Sarosdy, M. F.: Detection of recurrent bladder cancer using a new quantitative assay for bladder tumor antigen. J. Urol., part 2, 157: 337, abstract 1317, 1997.
38. Leyh, H., Marberger, M., Pagano, F., Bassi, P., Sternberg, C. N., Pansadoro, V., Conort, P., Boccon-Gibod, L. and Thoelke, K. R.: Results of a European multicenter trial comparing the BTA stat test to urine cytology in patients suspected of having bladder cancer. J. Urol., part 2, 157: 337, abstract 1316, 1997.
39. Sarosdy, M. F., Hudson, M. A., Ellis, W. J., Soloway, M. S., de Vere White, R., Sheinfeld, J., Jarowenko, M. V., Schellhammer, P. F., Schervish, E. W., Patel, J. V., Chodak, G. W., Lamm, D. L., Johnson, R. D., Henderson, M., Adams, G., Blumenstein, B. A., Thoelke, K. R., Pfalzgraf, R. D., Murchinson, H. A. and Brunelle, S. L.: Improved detection of recurrent bladder cancer using the Bard BTA stat Test. Urology, 50: 349, 1997.
40. Sarosdy, M. F., Hudson, M. A., Ellis, W. J., Soloway, M. S., de Vere White, R. W., Sheinfield, J., Jarowenko, M. V., Schellhammer, P. F., Messing, E. M., Schervish, E. W., Patel, J. V., Chocak, G. W., Lamm, D. L., Johnson, R. D., Henderson, M., Adams, G., Blumenstein, B. A., Toelke, K. R., Brunelle, S. L., Pfalzgraf, R. D. and Murchinson, H. A.: Detection of recurrent bladder cancer using a new one-step test for bladder tumor antigen. J. Urol., part 2, 157: 337, abstract 1318, 1997.
41. Soloway, M. S., Briggman, J. V., Carpinito, G. A., Chodak, G. W., Church, P. A., Lamm, D. L., Lange, P., Messing, E., Pasciak, R. M., Reservitz, G. B., Rukstalis, D. B., Sarosdy, M. F., Stadler, W. M., Thiel, R. P. and Hayden, C. L.: Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J. Urol., 156: 363, 1996.
42. Akaza, H., Miyanaga, N., Tsukamoto, T., Ishikawa, S., Ohtani, M., Noguchi, R., Kawabe, K., Kubota, Y., Fujita, K., Obata, K., Hirao, Y., Kotake, T., Ohmori, H., Kumazawa, J. and Koiso, K.: Evaluation of nuclear matrix protein 22 (NMP22) as a diagnostic marker for bladder cancer: a multicenter trial in Japan. J. Urol., part 2, 157: 337, abstract 1315, 1997.
43. Carpinito, G. A., Stadler, W. M., Briggman, J. V., Chodak, G. W., Church, P. A., Lamm, D. L., Lange, P. H., Messing, E. M., Pasciak, R. M., Reservitz, G. B., Ross, R. N., Rukstalis, D. B., Sarosdy, M. F., Soloway, M. S., Thiel, R. P., Vogelzang, N. and Hayden, C. L.: Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J. Urol., 156: 1280, 1996.
44. Rodriguez-Villanueva, J. R., Dinney, C. P. N., Grossman, H. B. and Fritsche, H. A.: Evaluation of the NMP22 immunoassay in the detection of transitional cell carcinoma (TCC) of the urinary tract. J. Urol., part 2, 157: 336, abstract 1314, 1997.
45. Gerdes, J., Schwab, U., Lemke, H. and Stein, H.: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int. J. Cancer, 31: 13, 1983.
46. Loke, S. L., Jaffe, E. S. and Neckers, L. M.: Inhibition of in vitro DNA synthesis by the monoclonal antibody Ki-67. Blood, suppl., 70: 1579, 1987.
47. Brown, D. C. and Gatter, K. C.: Monoclonal antibody Ki-67: its use in histopathology. Histopathology, 17: 489, 1990.
48. Okamura, K., Miyake, K., Koshikawa, T. and Asai, J.: Growth fractions of transitional cell carcinomas of the bladder defined by the monoclonal antibody Ki-67. J. Urol., 144: 875, 1990.
49. Fontana, D., Bellina, M., Gubetta, L., Fasolis, G., Rolle, L., Scoffone, C., Porpiglia, F., Colombo, M., Tarabuzzi, R. and Leonardo, E.: Monoclonal antibody Ki-67 in the study of the proliferative activity of bladder carcinoma. J. Urol., 148: 1149, 1992.
50. Cohen, M. B., Waldman, F. M., Carroll, P. R., Kerschmann, R., Chew, K. and Mayall, B. H.: Comparison of five histopathologic methods to assess cellular proliferation in transitional cell carcinoma of the urinary bladder. Hum. Path., 24: 772, 1993.
51. Tsujihashi, H., Nakanishi, A., Matsuda, H., Uejima, S. and Kurita, T.: Cell proliferation of human bladder tumors deter-mined by BrdUrd and Ki-67 immunostaining. J. Urol., 145: 846, 1991.
52. Mulder, A. H., Van Hootegem, J. C., Sylvester, R., ten Kate, F. J., Kurth, K. H., Ooms, E. C. and Van der Kwast, T. H.: Prognostic factors in bladder carcinoma: histologic parameters and expression of a cell cycle-related nuclear antigen (Ki-67). J. Path., 166: 37, 1992.
53. Bush, C., Price, P., Norten, J., Parkins, C. S., Bailey, M. J., Boyd, J., Jones, C. R., A'Hern, R. P. and Horwich, A.: Proliferation in human bladder carcinoma measured by Ki-67 antibody labelling: its potential clinical importance. Brit. J. Cancer, 64: 357, 1991.
54. King, E. D., Matteson, J., Jacobs, S. C. and Kyprianou, N.: Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression. J. Urol., 155: 316, 1996.
55. Ogata, K., Celis, J. E. and Tan, E. M.: Proliferating cell nuclear antigen: cyclin. Methods Enzymol., 150: 147, 1987.
56. Robbins, B. A., de la Vega, D., Ogata, K., Tan, E. M. and Nakamura, R. N.: Immunohistochemical detection of proliferating cell nuclear antigen in solid human malignancies. Arch. Path. Lab. Med., 111: 841, 1987.
57. Kroft, S. H. and Oyasu, R.: Urinary bladder cancer: mechanisms of development and progression. Lab. Invest., 71: 158, 1994.
58. Strohmeyer, T. G. and Slamon, D. J.: Proto-oncogenes and tumor suppressor genes in human urological malignancies. J. Urol., 151: 1479, 1994.
59. Moriyama, N., Umeda, T., Akaza, H., Taniguchi, J., Kitamura, T., Murakami, T., Kawabe, K. and Aso, Y.: Expression of ras p21 oncogene product on human bladder tumors. Urol. Int., 44: 260, 1989.
60. Nagata, Y., Abe, M., Kobayashi, K., Saiki, S., Kotake, T., Yoskikawa, K., Ueda, R., Nakayama, E. and Shiku, H.: Point mutation of c-gras gene in human bladder cancer and kidney cancer. Jap. J. Cancer Res., 81: 22, 1990.
61. Fradet, Y.: Markers of prognosis in superficial bladder cancer. Sem. Urol., 10: 28, 1992.
62. Czerniak, B., Deitch, D., Simmons, H., Etkind, P., Herz, F. and Koss, L. G.: Ha-ras gene condon 12 mutation and DNA ploidy in urinary bladder carcinoma. Brit. J. Cancer, 62: 762, 1990.
63. Stanley, L. A.: Molecular aspects of chemical carcinogenesis: the roles of oncogenes and tumour suppressor genes. Toxicology, 96: 173, 1995.
64. Fontana, D., Bellina, M., Scoffone, C., Cagnazzi, E., Cappia, S., Cavallo, F., Russo, R. and Leonardo, E.: Evaluation of c-ras oncogene product (p21) in superficial bladder cancer. Eur. Urol., 29: 470, 1996.
65. Evan, G. I. and Littlewood, T. D.: The role of c-myc in cell growth. Curr. Opin. Gen. Dev., 3: 44, 1993.
66. Koskinen, P. J. and Alitalo, K.: Role of myc amplification and overexpression in cell growth, differentiation and death. Sem. Cancer Biol., 4: 3, 1993.
67. Cole, M. D.: The myc oncogene: its role in transformation and differentiation. Ann. Rev. Gen., 20: 361, 1986.
68. Watt, R. A., Shatzman, A. R. and Rosenberg, M.: Expression and characterization of the human c-myc DNA binding protein. Mol. Cell Biol., 5: 448, 1985.
69. Roux-Dossetto, M., Romain, S., Dussault, N., Desideri, C., Piana, L., Bonnier, P., Tubiana, N. and Martin, P. M.: c-myc gene amplification in selected node-negative breast cancer patients correlates with high rate of relapse. Eur. J. Cancer, 28A: 1600, 1992.
70. Berns, E. M., Klijn, J. G., van Putten, W. L., van Staveren, I. L., Potengen, H. and Foekens, J. A.: c-myc amplification is a better prognostic factor then Her2/neu amplification in primary breast cancer. Cancer Res., 52: 1107, 1992.
71. Kotake, T., Saiki, S., Kinouchi, T., Shiku, H. and Nakayama, E.: Detection of c-myc gene product in urinary bladder cancer. Jap. J. Cancer Res., 81: 1198, 1990.
72. Lipponen, P. K.: Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer. J. Path., 175: 203, 1995.
73. Momand, J., Zambetti, G. P., Olson, D. C., George, D. and Levine, A. J.: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53 mediated transactivation. Cell, 69: 1237, 1992.
74. Habuchi, T., Kinoshita, H., Yamada, H., Kakehi, Y., Ogawa, O., Wu, W. J., Takahashi, R., Sugiyama, T. and Yoshida, O.: Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification. J. Natl. Cancer Inst., 86: 1331, 1994.
75. Lianes, P., Orlow, I., Zhang, Z. F., Oliva, M. R., Sarkis, A. S., Reuter, V. E. and Cordon-Cardo, C.: Altered patterns of MDM2 and TP53 expression in human bladder cancer. J. Natl. Cancer Inst., 86: 1325, 1994.
76. Underwood, M., Bartlett, J., Reeves, J., Gardiner, S., Scott, R. and Cooke, T.: C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors? Cancer Res., 55: 2422, 1995.
77. Bargmann, C. I., Hung, M. C. and Weinberg, R. A.: The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature, 319: 226, 1986.
78. Yamamoto, T., Ikawa, S., Akiyama, T., Semba, K., Nomura, N., Miyajima, N., Saito, T. and Toyoshima, K.: Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor. Nature, 319: 230, 1986.
79. Stern, D. F., Heffernan, P. A. and Weinberg, R. A.: p185, a product of the neu proto-onogene, is a receptorlike protein associated with tyrosine kinase activity. Mol. Cell. Biol., 6: 1729, 1986.
80. Akiyama, T., Sudo, C., Ogawara, H., Toyoshima, K. and Yamamoto, T.: The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science, 232: 1644, 1986.
81. Lee, J., Dull, T. J., Lax, I., Schlessinger, J. and Ullrich, A.: HER2 cytoplasmic domain generates normal mitogenic and transforming signals in a chimeric receptor. EMBO J., 8: 167, 1989.
82. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A. and Press, M. F.: Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science, 244: 707, 1989.
83. Borg, A., Baldetorp, B., Ferno, M., Killander, D., Olsson, H. and Sigurdsson, H.: ERBB-2 amplification in breast cancer with a high rate of proliferation. Oncogene, 6: 137, 1991.
84. Gorgoulis, V. G., Barbatis, C., Poulias, I. and Karameris, A. M.: Molecular and immunohistochemical evaluation of epidermal growth factor receptor and c-erbB-2 gene product in transitional cell carcinomas of the urinary bladder: a study in Greek patients. Modern Path., 8: 758, 1995.
85. Sato, K., Moriyama, M., Mori, S., Saito, M., Watanuki, T., Terada, K., Okuhara, E., Alkeiyama, T., Toyoshima, K., Yamamoto, T. and Kato, T.: An immunohistologic evaluation of c-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer, 70: 2493, 1992.
86. Moch, H., Sauter, G., Moore, D., Mihatsch, M. J., Gudat, F. and Waldman, F.: p53 and erbB-2 protein overexpression are associated with early invasion and metastasis in bladder cancer. Virchows Arch. A. Path. Anat. Histopath., 423: 329, 1993.
87. Moriyama, M., Akiyama, T., Yamamoto, T., Kawamoto, T., Kato, T., Sato, K., Watanuki, T., Hikage, T., Katsuta, N. and Mori, S.: Expression of c-erbB-2 gene product in urinary bladder cancer. J. Urol., 145: 423, 1991.
88. Lipponen, P.: Expression of c-erbB-2 oncoprotein in transitional cell bladder cancer. Eur. J. Cancer, 29A: 749, 1993.
89. Mellon, J. K., Lunec, J., Wright, C., Horne, C. H. W., Kelly, P. and Neal, D. E.: c-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. J. Urol., 155: 321, 1996.
90. Lipponen, P. and Eskelinen, M.: Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, onocprotein (c-erbB-2, p53) expression and long-term prognosis. Brit. J. Cancer, 69: 1120, 1994.
91. Adamson, E. D. and Rees, A. R.: Epidermal growth factor receptors. Mol. Cell. Biochem., 34: 129, 1981.
92. Massague, J.: EGF-like TGF. J. Biol. Chem., 258: 13614, 1983.
93. Partanen, A. M.: Epidermal growth factor and transforming growth factor-alpha in the development of epithelial-mesenchymal organs of the mouse. Curr. Top. Dev. Biol., 24: 31, 1990.
94. Mellon, J. K., Cook, S., Chambers, P. and Neal, D. E.: Tranforming growth factor alpha and epidermal growth factor in bladder cancer and their relationship to epidermal growth factor receptor. Brit. J. Cancer, 73: 654, 1996.
95. Messing, E. M. and Reznikoff, C. A.: Epidermal growth factor and its receptor: markers of- and targets for-chemoprevention of bladder cancer. J. Cell. Biochem., suppl., 161: 56, 1992.
96. Liebert, M.: Growth factors in bladder cancer. World J. Urol., 13: 349, 1995.
97. Messing, E. M.: Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma. Cancer Res., 50: 2530, 1990.
98. Neal, D. E., Sharples, L., Smith, K., Frennelly, J., Hall, R. R. and Harris, A. L.: The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer, 65: 1619, 1990.
99. Sauter, G., Haley, J., Chew, K., Kerschmann, R., Moore, D., Carroll, P., Moch, H., Gudat, F., Mihatsch, M. J. and Waldman, F.: Epidermal growth-factor-receptor expression is associated with rapid tumor proliferation in bladder cancer. Int. J. Cancer, 57: 508, 1994.
100. Berger, M. S., Greenfield, C., Gullick, W. J., Haley, J., Downward, J., Neal, D. E., Harris, A. L. and Waterfield, M. D.: Evaluation of epidermal growth factor receptors in bladder tumours. Brit. J. Cancer, 56: 533, 1987.
101. Neal, D. E., Marsh, C., Bennett, M. K., Abel, P. D., Hall, R. R., Sainsbury, J. R. C. and Harris, A. L.: Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet, 1: 366, 1985.
102. Messing, E. M., Hanson, P., Ulrich, P. and Erturk, E.: Epidermal growth factor-interactions with normal and malignant urothelium: in vivo and in situ studies. J. Urol., 138: 1329, 1987.
103. Neal, D. E., Smith, K., Fennelly, J., Bennett, M. K., Hall, R. R. and Harris, A. L.: The epidermal growth factor receptor in human bladder cancer: a comparison of immunohistochemistry and ligand binding. J. Urol., 141: 517, 1989.
104. Lönn, U., Lönn, S., Nylén, U., Friberg, S. and Stenkvist, B.: Gene amplification detected in carcinoma cells from human urinary bladder washings by the polymerase chain reaction method. Cancer, 71: 3605, 1993.
105. Yura, Y., Hayashi, O., Kelly, M. and Oyasu, R.: Identification of epidermal growth factor as a component of rat urinary bladder tumor-enhancing urinary fractions. Cancer Res., 49: 1548, 1989.
106. Kuranami, M., Yamaguchi, K., Fuchigami, M., Imanishi, K., Watanabe, T., Abe, K., Asanuma, F. and Hiki, Y.: Effect of urine of clonal growth of human bladder cancer cell lines. Cancer Res., 51: 4631, 1991.
107. Matilla, A-L., Saario, I., Viinikka, L., Ylikorkala, O. and Perheentupa, J.: Urinary epidermal growth factor concentrations in various human malignancies. Brit. J. Cancer, 57: 139, 1988.
108. Kristensen, J. K., Lose, G., Lund, F. and Nexo, E.: Epidermal growth factor in urine from patients with urinary bladder tumors. Eur. Urol., 14: 313, 1988.
109. Fuse, H., Mizuno, I., Sakamoto, M. and Katayama, T.: Epidermal growth factor in urine from the patients with urothelial tumors. Urol. Int., 48: 261, 1992.
110. Messing, E. M. and Murphy-Brooks, N.: Recovery of epidermal growth factor in voided urine of patients with bladder cancer. Urology, 44: 502, 1994.
111. Ravery, V., Grignon, D., Angulo, J., Pontes, E., Montie, J., Crissman, J. and Chopin, D.: Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer. Urol. Res., 25: 9, 1997.
112. Chodak, G. W., Hospelhorn, V., Judge, S. M., Mayforth, R., Koeppen, H. and Sasse, J.: Increased levels of fibroblast growth factor-like activity in urine from patients with bladder or kidney cancer. Cancer Res., 48: 2083, 1988.
113. Vallés, A. M., Boyer, B., Badet, J., Tucker, G. C., Barritault, D. and Thiery, J. P.: Acidic fibroblast growth factor is a modulator of epithelial plasticity in a rat bladder carcinoma cell line. Proc. Natl. Acad. Sci., 87: 1124, 1990.
114. Jouanneau, J., Gavrilovic, J., Caruelle, D., Jaye, M., Moens, G., Caruelle, J. P. and Thiery, J. P.: Secreted or nonsecreted forms of acidic fibroblast growth factor produced by transfected epithelial cells influence cell morphology, motility, and invasive potential. Proc. Natl. Acad. Sci., 88: 2893, 1991.
115. Chopin, D. K., Caruelle, J-P., Colombel, M., Palcy, S., Ravery, V., Caruelle, D., Abbou, C. C. and Barritault, D.: Increased immunodetection of acidic fibroblast growth factor in bladder cancer, detectable in urine. J. Urol., 150: 1126, 1993.
116. Nguyen, M., Watanabe, H., Budson, A. E., Richie, J. P. and Folkman, J.: Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J. Natl. Cancer Inst., 85: 241, 1993.
117. O'Brien, T. S., Smith, K., Cranston, D., Fuggle, S., Bicknell, R. and Harris, A. L.: Urinary basic fibroblast growth factor in patients with bladder cancer and benign prostatic hypertrophy. Brit. J. Urol., 76: 311, 1995.
118. Nguyen, M., Watanabe, H., Budson, A. E., Richie, J. P., Hayes, D. F. and Folkman, J.: Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J. Natl. Cancer Inst., 86: 356, 1994.
119. Kehrl, J. H.: Transforming growth factor-beta: an important mediator of immunoregulation. Int. J. Cell Cloning, 9: 438, 1991.
120. Eder, I. E., Stenzl, A., Hobisch, A., Cronauer, M. V., Bartsch, G. and Klocker, H.: Transforming growth factors β-1 and β-2 in serum and urine from patients with bladder cancer. J. Urol., 156: 953, 1996.
121. Miyamoto, H., Kubota, Y., Shuin, T., Torigoe, S., Dobashi, Y. and Hosaka, M.: Expression of transforming growth factor-beta-1 in human bladder cancer. Cancer, 75: 2565, 1995.
122. Eder, I. E., Stenzl, A., Hobisch, A., Cronauer, M. V., Bartsch, G. and Klocker, H.: Expression of transforming growth factors beta-1, beta 2 and beta 3 in human bladder carcinomas. Brit. J. Cancer, 75: 1753, 1997.
123. Coombs, L. M., Pigott, D. A., Eydmann, M. E., Proctor, A. J. and Knowles, M. A.: Reduced expression of TGF beta is associated with advanced disease in transitional cell carcinoma. Brit. J. Cancer, 67: 578, 1993.
124. Gavriloc, J., Moens, G., Thiery, J. P. and Jouanneau, J.: Expression of transfected transforming growth factor alpha induces a motile fibroblast-like phenotype with extracellular matrix-degrading potential in a rat bladder carcinoma cell line. Cell Regulation, 1: 1003, 1990.
125. Cohen, M. B., Griebling, T. L., Ahaghotu, C. A., Rokhlin, O. W. and Ross, J. S.: Cellular adhesion molecules in urologic malignancies. Amer. J. Clin. Path., 107: 56, 1997.
126. Takeichi, M.: The cadherins: cell-cell adhesion molecules controlling animal morphogenesis. Development, 102: 639, 1988.
127. Takeichi, M.: Cadherin cell adhesion receptors as a morphogenetic regulator. Science, 251: 1451, 1991.
128. Frixen, U. H., Behrens, J., Sachs, M., Eberle, G., Voss, B., Warda, A., Löchner, D. and Birchmeier, W.: E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J. Cell Biol., 113: 173, 1991.
129. Bringuier, P. P., Umbas, R., Schaafsma, H. E., Karthaus, H. F., Debruyne, F. M. J. and Schalken, J. A.: Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res., 53: 3241, 1993.
130. Otto, T., Birchmeier, W., Schmidt, U., Hinke, A., Schipper, J., Rübben, H. and Raz, A.: Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder cancer. Cancer Res., 54: 3120, 1994.
131. Lipponen, P. K. and Eskelinen, M. J.: Reduced expression of E-cadherin is related to invasive disease and frequent recurrence in bladder cancer. J. Cancer Res. Clin. Oncol., 121: 303, 1995.
132. Syrigos, K. N., Krausz, T., Waxman, J., Pandha, H., Rowlinson-Busza, G., Verne, J., Epenetos, A. A. and Pignatelli, M.: E-cadherin expression in bladder cancer using formalin-fixed, paraffin-embedded tissues: correlation with histopathological grade, tumour stage and survival. Int. J. Cancer, 64: 367, 1995.
133. Giroldi, L. A., Bringuier, P. P. and Schalken, J. A.: Defective E-cadherin function in urological cancers: clinical implications and molecular mechanisms. Invasion Metastasis, 14: 71, 1994.
134. Ross, J. S., del Rosario, A. D., Figge, H. L., Sheehan, C., Fisher, H. A. and Bui, H. X.: E-cadherin expression in papillary transitional cell carcinoma of the urinary bladder. Hum. Path., 26: 940, 1995.
135. Shimazui, T., Schalken, J. A., Giroldi, L. A., Jansen, C. F., Akaza, H., Koiso, K., Debruyne, F. M. and Bringuier, P. P.: Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma catenins and p120cas) in bladder tumors. Cancer Res., 56: 4154, 1996.
136. Banks, R. E., Porter, W. H., Whelan, P., Smith, P. H., Selby, P. J.: Soluble forms of the adhesion molecule E-cadherin in urine. J. Clin. Path., 48: 179, 1995.
137. Griffiths, T. R., Brotherick, I., Bishop, R. I., White, M. D., McKenna, D. M., Horne, C. H., Shenton, B. K., Neal, D. E. and Mellon, J. K.: Cell adhesion molecules in bladder cancer: soluble serum E-cadherin correlates with predictors of recurrence. Brit. J. Cancer, 74: 579, 1996.
138. Albeda, S. M.: Biology of disease: role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab. Invest., 68: 4, 1993.
139. Symington, B. E., Takada, Y. and Carter, W. G.: Interaction of intergrins alpha 3 beta 1 and alpha 2 beta 1: potential role in keratinocyte intercellular adhesion. J. Cell Biol., 120: 523, 1993.
140. Liebert, M., Wedemeyer, G., Stein, J., Washington, R. W., Jr., Van Waes, C., Carey, T. E. and Grossman, H. B.: The monoclonal antibody BQ16 identifies the alpha 6 beta 4 integrin on bladder cancer. Hybridoma, 12: 67, 1993.
141. Liebert, M., Washington, R., Stein, J., Wedemeyer, G. and Grossman, B.: Expression of the VLA beta 1 integrin family in bladder cancer. Amer. J. Path., 144: 1016, 1994.
142. Saito, T., Kimura, M., Kawasaki, T., Sato, S. and Tomita, Y.: Correlation between integrin alpha 5 expression and the malignant phenotype of transitional cell carcinoma. Brit. J. Cancer, 73: 327, 1996.
143. Liebert, M., Washington, R., Wedemeyer, G., Carey, T. E. and Grossman, H. B.: Loss of co-localization of alpha 6 beta 4 integrin and collagen VII in bladder cancer. Amer. J. Path., 144: 787, 1994.
144. Folkman, J., Cole, P. and Zimmerman, S.: Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Ann. Surg., 164: 491, 1966.
145. Sutherland, R. M., McCredie, J. A. and Inch, W. R.: Growth of multicell spheroids in tissue culture as a model of nodular carcinomas. J. Natl. Cancer Inst., 46: 113, 1971.
146. Gimbrone, M. A., Jr., Leapman, S. B., Coltran, R. S. and Folkman, J.: Tumor dormancy in vivo by prevention of neovascularization. J. Exp. Med., 136: 261, 1972.
147. Gimbrone, M. A., Jr., Cotran, R. S., Leapman, S. B. and Folkman, J.: Tumor growth neovascularization: an experimental model using the rabbit cornea. J. Natl. Cancer Inst., 52: 413, 1974.
148. O'Reilly, M. S., Holmgren, L., Chen, C. and Folkman, J.: Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med., 2: 689, 1996.
149. LeQuerrec, A., Duval, D. and Tobelem, G.: Tumour angiogenesis. Baillieres Clin. Haematol., 6: 711, 1993.
150. Blood, C. H. and Zetter, B. R.: Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochem. Biophys. Acta, 1032: 89, 1990.
151. Polverini, P. J. and Leibovich, S. J.: Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages. Lab. Invest., 51: 635, 1984.
152. Folkman, J. and Klagsburn, M.: Angiogenic factors. Science, 235: 442, 1987.
153. Srivastava, A., Laidler, P., Davies, R. P., Horgan, K. and Hughes, L. E.: The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma. A quantitative histologic study. Amer. J. Path., 133: 419, 1988.
154. Barnhill, R. L. and Levy, M. A.: Regressing thin cutaneous malignant melanomas (< or = 1.0 mm) are associated with angiogenesis. Amer. J. Path., 143: 99, 1992.
155. Weidner, N., Folkman, J., Pozza, F., Bevilacqua, P., Allred, E. N., Moore, D. H., Meli, S. and Gasparini, G.: Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl. Cancer Inst., 84: 1875, 1992.
156. Horak, E. R., Leek, R., Klenk, N., LeJeune, S., Smith, K., Stuart, N., Greenall, M., Stepniewska, K. and Harris, A. L.: Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet, 340: 1120, 1992.
157. Weidner, N., Carrol, P. R., Flax, J., Blumenfeld, W. and Folkman, J.: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Amer. J. Path., 143: 401, 1993.
158. Brawer, M. K., Deering, R. E., Brown, M., Preston, S. D. and Bigler, S. A.: Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer, 73: 678, 1994.
159. Bochner, B. H., Cote, R. J., Weidner, N., Groshen, S., Chen, S-C., Skinner, D. G. and Nichols, P. W.: Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J. Natl. Cancer Inst., 87: 1603, 1995.
160. Jaeger, T. M., Weidner, N., Chew, K., Moore, D. H., Kerschmann, R. L., Waldman, F. M. and Carroll, P. R.: Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J. Urol., 154: 69, 1995.
161. Dickinson, A. J., Fox, S. B., Persad, R. A., Hollyer, J., Sibley, G. N. and Harris, A. L.: Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Brit. J. Urol., 74: 762, 1994.
162. O'Brien, T., Cranston, D., Fuggle, S., Dicknell, R. and Harris, A. L.: Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res., 55: 510, 1995.
163. Cambell, S. C. and Bouck, N.: Harnessing the tumor-fighting power of angiogenesis. Contemp. Urol., June, pp. 27-40, 1996.
164. D'Amato, R. J., Loughnan, M. S., Flynn, E. and Folkman, J.: Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci., 91: 4082, 1994.
165. Voest, E. E., Kenyon, B. M., O'Reilly, M. S., Truitt, G., D'Amato, R. J. and Folkman, J.: Inhibition of angiogenesis in vivo by interleukin 12. J. Natl. Cancer Inst., 87: 581, 1995.
166. O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., Lane, W. S., Cao, Y., Sage, E. H. and Folkman, J.: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis Lung carcinoma. Cell, 79: 315, 1994.
167. O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Cao, Y., Moses, M., Lane, W. S., Sage, E. H. and Folkman, J.: Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold Spring Harbor Symposia Quant. Biol., 59: 471, 1994.
168. Iruela-Arispe, M. L., Bornstein, P. and Sage, H.: Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro. Proc. Natl. Acad. Sci., 88: 5026, 1991.
169. Good, D. J., Polverini, P. J., Rastinejad, F., LeBeau, M. M., Lemons, R. S., Frazier, W. A. and Bouck, N. P.: A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci., 87: 6624, 1990.
170. Grossfeld, G. D., Shi, S. R., Ginsberg, D. A., Rich, K. A., Skinner, D. G., Taylor, C. R. and Cote, R. J.: Immunohistochemical detection of thrombospondin-1 in formalin-fixed, paraffin-embedded tissue. J. Histochem. Cytochem., 44: 761, 1996.
171. Cordon-Cardo, C., Wartinger, D., Petrylak, D., Dalbagni, G., Fair, W. R., Fuks, Z. and Reuter, V. E.: Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J. Natl. Cancer Inst., 84: 1251, 1992.
172. Dameron, K. M., Volpert, O. V., Tainsky, M. A. and Bouck, N.: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science, 265: 1582, 1994.
173. Grossfeld, G. D., Ginsberg, D. A., Stein, J. P., Bochner, B. H., Esrig, D., Groshen, S., Dunn, M., Nichols, P. W., Taylor, C. R., Skinner, D. G. and Cote, R. J.: Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis and tumor progression. J. Natl. Cancer Inst., 89: 219, 1997.
174. Folkman, J.: Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. New Engl. J. Med., 333: 1757, 1995.
175. Cordon-Cardo, C.: Mutation of cell cycle regulators. Biological and clinical implications of human neoplasia. Amer. J. Path., 147: 545, 1995.
176. Fung, Y-K., Murphree, A. L., T'Ang, A., Qian, J., Hinrichs, S. H. and Benedict, W. F.: Structural evidence for the authenticity of the human retinoblastoma gene. Science, 236: 1657, 1987.
177. Cairns, P., Proctor, A. J. and Knowles, M. A.: Loss of heterozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma. Oncogene, 6: 2305, 1991.
178. Logothetis, C. J., Xu, H-J., Ro, J. Y., Hu, S-X., Sahin, A., Ordonez, N. and Benedict, W. F.: Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J. Natl. Cancer Inst., 84: 1256, 1992.
179. Presti, J. C., Jr., Reuter, V. E., Galan, T., Fair, W. R. and Cordon-Cardo, C.: Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res., 51: 5405, 1991.
180. Bagchi, S., Weinman, R. and Raychaudhuri, P.: The retinoblastoma protein copurifies with E2F-I, and E1A-regulated inhibitor of the transcription factor E2F. Cell, 65: 1063, 1991.
181. Wang, J. Y., Knudsen, E. S. and Welch, P. J.: The retinoblastoma tumor suppressor protein. Adv. Cancer Res., 64: 25, 1994.
182. Geradts, J., Hu, S-X., Lincoln, C., Benedict, W. F. and Xu, H-J.: Aberrant RB gene expression in routinely processed, archival tumor tissues determined by three different anti-RB antibodies. Int. J. Cancer, 58: 161, 1994.
183. Xu, H-J., Cairns, P., Hu, S-X., Knowles, M. A. and Benedict, W. F.: Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression. Int. J. Cancer, 53: 781, 1993.
184. Ishikawa, J., Xu, H-J., Hu, S-X., Yandell, D. W., Maeda, S., Kamidono, S., Benedict, W. F. and Takahashi, R.: Inactivation of the retinoblastoma gene in human bladder and renal cell carcinomas. Cancer Res., 51: 5736, 1991.
185. Hollstein, M., Sidransky, D., Volgelstein, B. and Harris, C. C.: p53 mutations in human cancers. Science, 253: 49, 1991.
186. Lane, D. P.: Cancer. p53, guardian of the genome. Nature, 358: 15, 1992.
187. Dalbagni, G., Cordon-Cardo, C., Reuter, V. and Fair, W. R.: Tumor suppressor alterations in bladder cancer. Translation correlates to clinical practice. Surg. Oncol. Clin. N. Amer., 4: 231, 1995.
188. Esrig, D., Elmajian, D., Groshen, S., Freeman, J. A., Stein, J. P., Chen, S-C., Nichols, P. W., Skinner, D. G., Jones, P. A. and Cote, R. J.: Accumulation of nuclear p53 and tumor progression in bladder cancer. New Engl. J. Med., 331: 1259, 1994.
189. Cordon-Cardo, C., Dalbagni, G., Saez, G. T., Oliva, M. R., Zhang, Z-F., Rosai, J., Reuter, V. E. and Pellicer, A.: p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int. J. Cancer, 56: 347, 1994.
190. Lipponen, P. K.: Over-expression of the p53 nuclear oncoprotein in transitional cell carcinoma of the bladder and its prognostic value. Int. J. Cancer, 53: 365, 1993.
191. Sarkis, A. S., Dalbagni, G., Cordon-Cardo, C., Zhang, Z. F., Sheinfeld, J., Fair, W. R., Herr, H. W. and Reuter, V. E.: Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J. Natl. Cancer Inst., 85: 53, 1993.
192. Esrig, D., Shi, S-R., Bochner, B., Nichols, P. W., Chen, S-C., Yang, C., Jones, P., Skinner, D. G. and Cote, R. J.: Prognostic importance of p53 and Rb alterations in transitional cell carcinoma of the bladder. J. Urol., part 2, 153: 362A, abstract 536, 1995.
193. Lerner, S. P., Linn, D., Chakraborty, S., Trong, L., Xu, H-J., Wheeler, T. M., Kattan, M. W. and Benedict, W. F.: Correlation of p53 and retinoblastoma protein expression with established pathologic prognostic features in radical cystoprostatectomy specimens. J. Urol., part 2, 153: 353A, abstract 537, 1995.
194. Michieli, P., Chedid, M., Lin, D., Pierce, J. H., Mercer, W. E. and Givol, D.: Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res., 54: 3391, 1994.
195. Bond, J. A., Blaydes, J. P., Rowson, J., Haughton, M. F., Smith, J. R., Wynford-Thomas, D. and Wyllie, F. S.: Mutant p53 rescues human diploid cells from senescence without inhibiting the induction of SDI1/WAF1. Cancer Res., 55: 2404, 1995.
196. Parker, S. B., Eichele, G., Zhang, P., Rawls, A., Sands, A. T., Bradley, A., Olson, E. N., Harper, J. W. and Elledge, S. J.: p53-independent expression of p21 Cip1 in muscle and other terminally differentiating cells. Science, 267: 1024, 1995.
197. Stein, J. P., Ginsberg, D. A., Grossfeld, G. D., Esrig, D., Freeman, J. A., Dickinson, M. G., Groshen, S., Nichols, P. A., Jones, P. A., Skinner, D. G. and Cote, R. J.: The effect of p21 expression on tumor progression in p53 altered bladder cancer. J. Urol., part 2, 155: 628A, abstract 1270, 1996.
198. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E. and Jacks, T.: p53 status and the efficacy of cancer therapy in vivo. Science, 266: 807, 1994.
199. Sarkis, A., Bajorin, D. F., Reuter, V. E., Herr, H. W., Netto, G., Zhang, Z. F., Schultz, P. K., Cordon-Cardo, C. and Scher, H. I.: Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J. Clin. Oncol., 13: 1384, 1995.
200. Cote, R. J., Esrig, D., Groshen, S., Jones, P. A. and Skinner, D. G.: p53 and treatment of bladder cancer (Letter to the Editor). Nature, 385: 123, 1997.
201. Waldman, T., Lengauer, C., Kinzler, K. W. and Vogelstein, B.: Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature, 381: 713, 1996.
202. Chen, C., Chin, J. E., Ueda, K., Clark, D. P., Pastan, I., Gottesman, M. M. and Roninson, I. B.: Internal duplication and homology with bacterial transport proteins in mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell, 47: 381, 1986.
203. Gros, P., Ben Neriah, Y. B., Croop, J. M. and Housman, D. E.: Isolation and expression of a complimentary DNA that confers multidrug resistance. Nature, 323: 728, 1986.
204. Endicott, J. A. and Ling, V.: The biochemistry of P-glycoprotein-mediated multidrug resistance. Ann. Rev. Biochem., 58: 137, 1989.
205. Sternberg, C. N., Yagoda, A., Scher, H. I., Watson, R. C., Herr, H. W., Morse, M. J., Sogani, P. C., Vaughan, E. D., Jr., Brander, N., Weiselberg, L. R., Geller, N., Hollander, P. S., Lipperman, R., Fair, W. R. and Whitmore, W. F., Jr.: M-VAC (methorexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J. Urol., 139: 461, 1988.
206. Naito, S., Sakamoto, N., Dotoh, S., Goto, K., Matsumoto, T. and Kumazawa, J.: Correlation between the expression of P-glycoprotein and multidrug-resistant phenotype in transitional cell carcinoma of the urinary tract. Eur. Urol., 22: 158, 1992.
207. Shinohara, N., Liebert, M., Wedemeyer, G., Chang, J. H. C. and Grossman, H. B.: Evaluation of multiple drug resistance in human bladder cancer cell lines. J. Urol., 150: 505, 1993.
208. Hasegawa, S., Abe, T., Maito, S., Kotoh, S., Kumazawa, J., Hipfner, D. R., Deeley, R. G., Cole, S. P. and Kuwano, M.: Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines. Brit. J. Cancer, 71: 907, 1995.
209. Nakagawa, M., Emoto, A., Nasu, N., Kanada, T., Kuwano, M., Cole, S. P. C. and Nomura, Y.: Clinical significance of multidrug resistance associated protein and P-glycoprotein in patients with bladder cancer. J. Urol., 157: 1260, 1997.
210. Montie, J. E. and Meyers, S. E.: Defining the ideal tumor marker for prostate cancer. Urol. Clin. N. Amer., 45: 247, 1997.